drug
tirbanibulin
Marketedupdated 3mo agoby Almirall SA
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying tirbanibulin
- phase4Tirbanibulin for Pediatric Warts
- phase3A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
- phase3Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead
- phase4A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
- phase4A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
- —Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
- phase4Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands
- phase3A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 7, 2027
298 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Sep 7, 2038compositionUS 10669236
- Mar 12, 2038method-of-use (U-3015)US 10617693
- Mar 12, 2038method-of-use (U-3015)US 11497750
- Dec 28, 2030compositionUS 73009314.4y
- Feb 2, 2029compositionUS 78514702.5y
- Dec 28, 2027formulationUS 103230011.4y
FDA exclusivities (1)
- Jun 7, 2027D-192New Indication (3y)298d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that